[{"orgOrder":0,"company":"Centre for Human Drug Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"Rintatolimod","moa":"Toll-like-3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Centre for Human Drug Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centre for Human Drug Research \/ Aim ImmunoTech","highestDevelopmentStatusID":"4","companyTruncated":"Centre for Human Drug Research \/ Aim ImmunoTech"},{"orgOrder":0,"company":"Intravacc","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Avacc 101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ CEPI","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ CEPI"},{"orgOrder":0,"company":"Intravacc","sponsor":"Cimcure","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Cimcure","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Cimcure"},{"orgOrder":0,"company":"Viroclinics Biosciences","sponsor":"University Of Queensland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Viroclinics Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Viroclinics Biosciences \/ University Of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"Viroclinics Biosciences \/ University Of Queensland"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Wageningen Bioveterinary Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Wageningen Bioveterinary Research","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Wageningen Bioveterinary Research"},{"orgOrder":0,"company":"Leyden Labs","sponsor":"Nanopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Leyden Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Leyden Labs \/ Nanopharm","highestDevelopmentStatusID":"4","companyTruncated":"Leyden Labs \/ Nanopharm"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Tracer","sponsor":"Akston Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tracer","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Tracer \/ Akston Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Tracer \/ Akston Biosciences"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"IAVI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"VSV\u2206G-SARS-CoV-2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Batavia Bioscience \/ IAVI","highestDevelopmentStatusID":"4","companyTruncated":"Batavia Bioscience \/ IAVI"},{"orgOrder":0,"company":"ISA Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ISA106","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ISA Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ISA Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ISA Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VSY Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"TR-C 19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"VSY Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VSY Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VSY Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Gonorrhea Vaccine Avacc 11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"NGoXIM","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ National Institutes of Health"},{"orgOrder":0,"company":"Intravacc","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Avacc 11","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Intravacc \/ CARB-X","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ CARB-X"},{"orgOrder":0,"company":"Micreos Human Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"XZ.700","moa":"Cell wall","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Micreos Human Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Micreos Human Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Micreos Human Health \/ Inapplicable"},{"orgOrder":0,"company":"Saillant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Saillant Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Saillant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Saillant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intravacc","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Zegocractin","moa":"CRAC channel","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Intravacc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intravacc \/ Beijing Zhifei Lvzhu Biopharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Intravacc \/ Beijing Zhifei Lvzhu Biopharmaceutical"},{"orgOrder":0,"company":"Hercules Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"HP163","moa":"Aryl hydrocarbon receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Hercules Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hercules Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Hercules Pharmaceuticals \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proceeds will fund Avacc 11, a vaccine against Neisseria gonorrhoeae, using Intravacc’s outer membrane vesicle (OMV) platform technology.

                          Product Name : Avacc 11

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 16, 2024

                          Lead Product(s) : Avacc 11

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : CARB-X

                          Deal Size : $0.6 million

                          Deal Type : Funding

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : MEndoC (XZ.700) is a world-class endolysin platform, as a topical treatment of the inflammatory skin symptoms associated with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity.

                          Product Name : XZ.700

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          July 03, 2023

                          Lead Product(s) : XZ.700

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Avacc 11 (gonorrhea vaccine avacc 11) is the prophylactic intranasal gonorrhea candidate vaccine, consisting of outer membrane vesicles and microsphere encapsulated interleukin-12 induced Th1-driven immunity, with circulating and genital antibodies to Ne...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 16, 2023

                          Lead Product(s) : Gonorrhea Vaccine Avacc 11

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : CEPI’s funding will support preclinical development and testing of Intravacc’s subunit vaccine candidate Avacc 101, which is based on its Outer Membrane Vesicle (OMV) platform.

                          Product Name : Avacc 101

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 10, 2022

                          Lead Product(s) : Avacc 101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : CEPI

                          Deal Size : $4.8 million

                          Deal Type : Funding

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The grant will support the NG vaccine, called NGoXIM, based on gonococcal OMVs combined with sustained-release microspheres containing recombinant human IL-12, and will be administered intranasally.

                          Product Name : NGoXIM

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 10, 2022

                          Lead Product(s) : NGoXIM

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : National Institutes of Health

                          Deal Size : $14.6 million

                          Deal Type : Funding

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Both parties will continue to collaborate to tailor the Avacc 3 concept vaccine for the respective territories, including upscaling, toxicology and clinical trials. Avacc 3 has significant advantages over existing whooping cough vaccines.

                          Product Name : Avacc 3

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 05, 2022

                          Lead Product(s) : Zegocractin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Beijing Zhifei Lvzhu Biopharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          July 21, 2021

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Nanopharm

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          08

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : ISA104 is an immunotherapy based on ISA's Synthetic Long Peptide (SLP®) technology designed to direct a strong and specific immune response against the hepatitis B virus (HBV), with the aim to cure chronically infected patients.

                          Product Name : ISA104

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          July 20, 2021

                          Lead Product(s) : ISA104

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Health Holland

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          09

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : ISA106 is an immunotherapy agent that is intended to treat patients with SARS-CoV2 infections, and prevent progressive pneumonia and further complications – thereby avoiding admission to hospital and ICU.

                          Product Name : ISA106

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          March 03, 2021

                          Lead Product(s) : ISA106

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : CHDR, will conduct and manage the proposed clinical study, titled “A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subject...

                          Product Name : Ampligen

                          Product Type : Oligonucleotide

                          Upfront Cash : Undisclosed

                          January 29, 2021

                          Lead Product(s) : Rintatolimod

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Aim ImmunoTech

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank